- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04253626
Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia
March 7, 2024 updated by: Deirdre Lyell, Stanford University
Evaluate the extent to which treatment of iron deficiency anemia beyond 24-34 weeks' gestation of pregnancy with intravenous iron increases hemoglobin compared to oral iron.
The investigators will test the hypothesis that pregnant women who are anemic in the second and third trimester are more likely to significantly increase their hemoglobin with intravenous iron as opposed to the usual standard of care, oral iron.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine/Lucile Packard Childrens Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Pregnant women 18 years old and above
- Hemoglobin < 11 g/dL, serum ferritin < 30 ug/dL and or transferrin saturation (TSAT) < 20%
- Between 24-34 weeks' pregnancy
- Singleton pregnancy
- Receiving prenatal care at Stanford/LPCH OB clinic and planning to deliver at LPCH
- Hemodynamically stable
Exclusion Criteria:
- Patients unable to give informed consent
- Known allergy/hypersensitivity to IV iron
- Inflammatory Bowel Disease or history of gastric bypass surgery
- Dialysis-dependent Chronic Kidney Disease/ ESRD
- Known Hemoglobinopathies such as sickle cell disease, beta-thalassemia, alpha thalassemia
- Folate/Vitamin B12 deficiency
- Known malignancy
- Medication allergy to Tylenol (acetaminophen)
- Hemoglobin above 12 or less than 7 g/dL
- Patients with complex past medical histories which may include history of multiple medication allergies (greater than 2 allergies), connective tissue disorder, etc.
- Diagnosis of placenta previa
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravenous iron
Participants will receive 510mg intravenous iron ferumoxytol, with a maximum of 2 doses based on the baseline hemoglobin level.
The ferumoxytol is administered as an infusion for approximately 15 - 30 minutes.
|
510mg intravenous ferumoxytol
|
Active Comparator: Oral iron
Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery.
For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin < 9.
|
325mg oral ferrous sulfate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Hemoglobin value before and after intervention
Time Frame: From the date of randomization to four weeks after the intervention
|
Hemoglobin is measured as g/dL at enrollment and after the study intervention
|
From the date of randomization to four weeks after the intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Deirdre Lyell, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 21, 2021
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
January 31, 2020
First Submitted That Met QC Criteria
February 3, 2020
First Posted (Actual)
February 5, 2020
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 54788
- K12HD103084 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Related
-
4YouandMeCambridge Cognition Ltd; Sema4; Evidation Health; Vector Institute of Artificial... and other collaboratorsCompletedPregnancy Related | Wearables | Pregnancy EarlyUnited States
-
Helen Keller InternationalEleanor Crook FoundationNot yet recruitingPregnancy Related | Supplementation | Postnatal Related
-
The University of Texas Health Science Center,...CompletedPregnancy Related | Pregnancy, High RiskUnited States
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Shaare Zedek Medical CenterUnknownPregnancy Related | Pregnancy, High Risk | Anesthesia
-
University of CopenhagenStanford UniversityNot yet recruiting
-
European Vaccine InitiativeKintampo Health Research Centre, Ghana; Groupe de Recherche Action en Sante; Fondation... and other collaboratorsRecruitingPregnancy RelatedBenin, Burkina Faso, Ghana, Malawi
-
Kahramanmaras Sutcu Imam UniversityNot yet recruitingPregnancy RelatedTurkey
-
Fondation Hôpital Saint-JosephRecruiting
-
German Institute of Human NutritionRecruiting
Clinical Trials on Ferumoxytol Injection [Feraheme]
-
Allegheny Singer Research Institute (also known...Active, not recruitingLiver Neoplasms | Hepatocellular Carcinoma | Liver Metastases | Liver Cancer | Liver Carcinoma | Hepatocellular Cancer | Hepatic Cirrhosis | Hepatic Carcinoma | Hepatic AtrophyUnited States
-
Michael IvNational Cancer Institute (NCI)WithdrawnChildhood Brain NeoplasmUnited States
-
Jason GagliaHarvard Medical School (HMS and HSDM); National Institute of Allergy and Infectious...Unknown
-
Brigham and Women's HospitalCompletedPulmonary EmbolismUnited States
-
Oregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedNervous System Diseases | Diagnostic ImagingUnited States
-
Brigham and Women's HospitalActive, not recruiting
-
Paul FinnCompletedPediatric Congenital Heart DiseaseUnited States
-
Sunnybrook Health Sciences CentreUnity Health TorontoCompleted
-
University of HawaiiOregon Health and Science UniversityCompletedHIV DementiaUnited States
-
Beau NakamotoNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsCompleted